Trial Profile
A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Mercaptopurine; Methotrexate; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results assessing responses after addition of VEN to hyper-CVD in newly diagnosed ALL, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 29 May 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Apr 2024.
- 03 Oct 2022 Planned primary completion date changed from 30 May 2023 to 30 Apr 2023.